Retatrutide has been the most talked-about weight loss peptide since its phase 2 results in 2023. Until this spring, all of that talk rested on one mid-stage study. That changed on May 21, when Eli Lilly released topline results from TRIUMPH-1, the first phase 3 obesity trial of the drug. On June 6 the full results were presented at the American Diabetes Association's 86th Scientific Sessions, together with a second phase 3 trial in type 2 diabetes called TRANSCEND-T2D-1.

This article walks through what TRIUMPH-1 tested, what it found, and which questions are still open.

What retatrutide is

Retatrutide is a once-weekly injectable that activates three hormone receptors: GIP, GLP-1 and glucagon. Semaglutide acts on GLP-1 alone. Tirzepatide acts on GIP and GLP-1. The glucagon piece is the new part. Glucagon receptor activity is thought to raise energy expenditure and help clear fat from the liver, which is one reason researchers expected retatrutide to push weight loss further than the dual agonists.

In the phase 2 trial published in the New England Journal of Medicine in 2023, participants on the 12 mg dose lost an average of 24.2% of their body weight at 48 weeks [1]. Phase 3 was meant to show whether that held up in a much larger group over a longer period.

How TRIUMPH-1 was designed

TRIUMPH-1 enrolled 2,339 adults with obesity, or with overweight plus at least one weight-related health problem. None had diabetes. Participants were randomized in equal groups to retatrutide 4 mg, 9 mg, 12 mg or placebo for 80 weeks [2].

Everyone on retatrutide started at 2 mg and stepped up every four weeks until reaching their assigned dose. The 4 mg group needed only one step. Inside the main trial sat two smaller "basket" trials: one for people with knee osteoarthritis pain and one for people with moderate-to-severe obstructive sleep apnea [3].

The weight loss numbers

Lilly reported results two ways, and the difference matters when you compare trials.

Using the efficacy estimand, which looks at people who stayed on treatment, average weight loss at 80 weeks was [2]:

  • 19.0% on 4 mg
  • 25.9% on 9 mg
  • 28.3% on 12 mg
  • 2.2% on placebo

Using the treatment-regimen estimand, which counts everyone randomized whether or not they stayed on the drug, the figures were 17.6%, 23.7% and 25.0%, against 3.9% on placebo [4].

A few secondary results stood out. On the 12 mg dose, 45.3% of participants lost at least 30% of their body weight, a level usually associated with bariatric surgery. 65.3% ended the trial with a BMI under 30, and 33.3% reached a BMI under 25 [2][3]. Among people who started with class 3 obesity (BMI of 40 or higher), 37.5% on 12 mg finished below a BMI of 30 [2].

There was also a pre-specified extension for 532 participants with a starting BMI of 35 or more. Those who continued on 12 mg through 104 weeks lost an average of 30.3% [3]. That points to weight loss still moving after 80 weeks in heavier participants, though the extension group was selected for people who tolerated their dose.

Knee pain and sleep apnea

The two basket trials are where TRIUMPH-1 adds something new to the incretin story.

In participants with knee osteoarthritis, retatrutide reduced the WOMAC pain score by up to 4.3 points from a baseline of 6.0 on a 10-point scale, a 73.1% reduction [3]. In participants with moderate-to-severe obstructive sleep apnea, the apnea-hypopnea index dropped by up to 36.1 events per hour from a baseline of 58.6, a 60.6% reduction [3].

Both conditions are mechanically linked to body weight, so some of this improvement is expected from weight loss alone. The trial was not built to separate the weight effect from any direct drug effect.

Heart and metabolic markers

At 80 weeks, retatrutide lowered triglycerides by up to 41.0%, non-HDL cholesterol by up to 24.2% and systolic blood pressure by up to 12.3 mmHg. Waist circumference fell by up to 9.5 inches [3]. These are risk factor changes. TRIUMPH-1 did not measure heart attacks or strokes, and those outcomes need their own trials.

Side effects and dropouts

The side effect profile looked like a stronger version of what people already see with GLP-1 drugs. Rates for 4 mg, 9 mg and 12 mg compared with placebo were [3]:

  • Nausea: 28.6%, 38.4%, 42.4% vs 14.8%
  • Diarrhea: 25.2%, 34.1%, 32.0% vs 13.5%
  • Constipation: 23.8%, 25.9%, 26.1% vs 10.9%
  • Vomiting: 10.6%, 22.8%, 25.3% vs 4.8%

Two less familiar signals deserve attention. Dysesthesia, an unpleasant or altered skin sensation, occurred in 5.1%, 12.3% and 12.5% of people on retatrutide compared with 0.9% on placebo. Urinary tract infections ran at 7.5% to 8.8% compared with 5.3% on placebo. Lilly said both were mostly mild to moderate and most cases resolved during treatment [3].

Discontinuation because of side effects was 4.1% on 4 mg, 6.9% on 9 mg and 11.3% on 12 mg, compared with 4.9% on placebo [3]. The 4 mg result is interesting. It produced roughly 19% weight loss with a dropout rate no higher than placebo, which could make it a practical option for people who struggle with escalation.

The diabetes trial

TRANSCEND-T2D-1 tested retatrutide in 537 adults with type 2 diabetes who were not on any glucose-lowering drugs. Over 40 weeks, A1C fell by up to 2.0 percentage points from a baseline of 7.9%. Up to 46% of participants reached an A1C below 5.7%, the cutoff for normal blood sugar. People on 12 mg lost 16.8% of their body weight, and Lilly noted that weight loss had not leveled off at 40 weeks [3]. These results were published in The Lancet alongside the ADA presentation.

How it compares

Cross-trial comparisons are rough because populations, durations and estimands differ. With that caveat, the 12 mg result sits above what Tirzepatide 15 mg produced in SURMOUNT-1, where the treatment-regimen estimand showed 20.9% weight loss at 72 weeks [5]. A head-to-head trial is the only clean way to settle the comparison. For our earlier side-by-side look, see Tirzepatide vs Retatrutide.

What is still unknown

Several big questions remain open. Cardiovascular outcome data are still coming. Longer safety follow-up will show whether dysesthesia and urinary infections stay mild. Results from TRIUMPH-2 (people with type 2 diabetes) and TRIUMPH-3 (people with cardiovascular disease) are expected later this year. And the drug is not approved anywhere. Lilly states that retatrutide is legally available only to participants in its clinical trials [3].

You can follow the research summaries and study list on our Retatrutide page.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug. Talk with a qualified healthcare provider before starting, stopping or changing any treatment.

Sources

  1. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389:514-526.
  2. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026.
  3. Eli Lilly and Company. Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea. June 6, 2026.
  4. Taylor NP. Lilly's triple-G drug drives deep weight loss in phase 3 trial. Fierce Biotech. May 21, 2026.
  5. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216.